osteoporosis

News

FDA rejects Amgen/UCB osteoporosis drug

The FDA has rejected Amgen and UCB’s Evenity (romosozumab) osteoporosis drug after a late-stage trial unexpectedly highlighted a potential cardiac safety risk.

News

abstract shapes, bone structure, 3d render, bone

Amgen/UCB's osteoporosis drug hit by cardio risk

Competitor to Amgen's Epogen also moves closer to market

News

Amgen/UCB reveal new osteoporosis drug data

But romosozumab missed secondary endpoint of non-vertebral fractures

R&D

Merck & Co. drops osteoporosis drug

Move boosts Amgen and UCB, which are developing a rival.

News

Amgen's Prolia succeeds in glucocorticoid-induced osteoporos...

Possible new use for well-established drug.

Articles

UCB: growing sales and growing bones

The specialist pharma company is set to expand into osteoporosis through its partnership with Amgen

FDA rejects Amgen/UCB osteoporosis drug

Amgen/UCB's osteoporosis drug hit by cardio risk

Amgen/UCB reveal new osteoporosis drug data

Merck & Co. drops osteoporosis drug

Amgen's Prolia succeeds in glucocorticoid-induced osteoporos...

UCB: growing sales and growing bones

ASCO26: AI supercharging gene-based cancer detection, with D...

Discover a new era of healthcare panel engagement: Grounded ...

osteoporosis

Editor's Picks